CS logo
small CS logo
Jiangsu Cancer Hospital

Nanjing, Jiangsu, China
南京市的医院

About Jiangsu Cancer Hospital


江苏省肿瘤医院,是中华人民共和国江苏省的一所医院,为三级甲等医院,位于南京市百子亭42号。
  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender
Lead Sponsor
# Trials

Clinical Trials at Jiangsu Cancer Hospital


During the past decade, Jiangsu Cancer Hospital conducted 137 clinical trials. In the 10-year time frame, 137 clinical trials started and 36 clinical trials were completed, i.e. on average, 26.3% percent of trials that started reached the finish line to date. In the past 5 years, 41 clinical trials started and 21 clinical trials were completed. i.e. 51.2% of trials that started reached the finish line.
Created with Highcharts 11.1.0TrialsTrials Trend - Last 10 Years191918182828181813131818171766222233117744111144Started TrialsCompleted Trails201520162017201820192020202120220102030
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
2003-04-18
2011-04-21
Completed
1,886
A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13
2006-01-01
2013-03-01
Completed
683
Safety and Efficacy of Palonosetron in Preventing Chemotherapy-induced Nausea and Vomiting
2006-04-01
2006-10-01
Completed
144
Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer
2008-12-09
2018-06-01
Completed
105
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
2008-10-16
2029-09-20
Recruiting
720
LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer
2008-12-03
2017-11-13
Completed
1,314
Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer
2009-07-01
2015-10-01
Terminated
102
Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
2009-08-25
2021-04-29
Completed
492

Rows per page:

1–100 of 177

Clinical Trials Sponsors and Collaborators


Out of the total clinical trials conducted in "Jiangsu Cancer Hospital" #1 sponsor was "Hoffmann-La Roche" with 30 trials, followed by "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 13 trials sponsored, "Jiangsu Cancer Institute & Hospital" with 10 trials sponsored, "Jiangsu HengRui Medicine Co., Ltd." with 8 trials sponsored and "Betta Pharmaceuticals Co., Ltd." with 8 trials sponsored. Other sponsors include 104 different institutions and companies that sponsored additional 70 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Jiangsu Cancer Hospital" #1 collaborator was "LinkDoc Technology (Beijing) Co. Ltd." with 9 trials as a collaborator, "Jiangsu Cancer Institute & Hospital" with 3 trials as a collaborator, "Eisai Inc." with 2 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator and "Tigermed Consulting Co., Ltd" with 2 trials as a collaborator. Other collaborators include 40 different institutions and companies that were collaborators in the rest 50 trials.
Created with Highcharts 11.1.0Top Leading Sponsors

Created with Highcharts 11.1.0Top Collaborators

Clinical Trials Conditions at Jiangsu Cancer Hospital


According to Clinical.Site data, the most researched conditions in "Jiangsu Cancer Hospital" are "Non-small Cell Lung Cancer" (12 trials), "Breast Cancer" (11 trials), "Gastric Cancer" (7 trials), "Esophageal Squamous Cell Carcinoma" (6 trials) and "Non-Small Cell Lung Cancer" (6 trials). Many other conditions were trialed in "Jiangsu Cancer Hospital" in a lesser frequency.

Clinical Trials Intervention Types at Jiangsu Cancer Hospital


Most popular intervention types in "Jiangsu Cancer Hospital" are "Drug" (155 trials), "Biological" (13 trials), "Procedure" (12 trials), "Other" (10 trials) and "Radiation" (10 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (36 trials), "Cisplatin" (12 trials), "Atezolizumab" (11 trials), "Docetaxel" (10 trials) and "Anlotinib" (9 trials). Other intervention names were less common.

Clinical Trials Genders at Jiangsu Cancer Hospital


The vast majority of trials in "Jiangsu Cancer Hospital" are 155 trials for "All" genders, 12 trials for "Female" genders and 10 trials for "Male" genders.

Clinical Trials Status at Jiangsu Cancer Hospital


Currently, there are 72 active trials in "Jiangsu Cancer Hospital". 3 are not yet recruiting, 41 are recruiting, 27 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 64 completed trials in Jiangsu Cancer Hospital, undefined suspended trials, and 8 terminated clinical trials to date.
Out of the total trials that were conducted in Jiangsu Cancer Hospital, 21 "Phase 1" clinical trials were conducted, 56 "Phase 2" clinical trials and 100 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 4 trials that are defined as “Not Applicable".
Created with Highcharts 11.1.0Trials By Phase

Created with Highcharts 11.1.0Trials Status